{"disease":{"id":"urinary-bladder-cancer","name":"urinary bladder cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05621837","title":"Quantifying Systemic Immunosuppression to Personalize Cancer Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05792033","title":"Multicentric Prospective T1 Urinary Bladder Cancer Registry","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT03924895","title":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":595,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04718948","title":"Multimodal Spectroscopy to Detect Urothelial Cancer in Urine","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Florence","has_results":false},{"nct_id":"NCT03433924","title":"An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.","phase":"","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04635566","title":"Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute","phase":"NA","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT06156787","title":"Patterns of Urinary Bladder Cancer in Darfur, Suda","phase":"","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"National Center for Gastroentestinal and Liver Disease","has_results":false},{"nct_id":"NCT03998579","title":"Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05946369","title":"Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT06115434","title":"Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05787938","title":"Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection","phase":"","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05072600","title":"Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT04812145","title":"Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07259798","title":"Histopathological Findings in En-Bloc vs Conventional Transurethral Resection of Bladder Tumors.","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT07165236","title":"Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor","phase":"","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Osijek University Hospital","has_results":false},{"nct_id":"NCT04861584","title":"Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT03636256","title":"Evaluation of NanoDoce® in Participants With Urothelial Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"NanOlogy, LLC","has_results":true},{"nct_id":"NCT06582849","title":"Enhanced Assistance During Radiotherapy for Unmet Essential Needs","phase":"NA","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06822010","title":"SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT05644041","title":"Intravesical Gem/Doce in Patients With NMIBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"University of Arizona","has_results":false},{"nct_id":"NCT02722538","title":"Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Taris Biomedical LLC","has_results":false},{"nct_id":"NCT05822934","title":"Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06630247","title":"A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT03335059","title":"Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Medical Enterprises Ltd.","has_results":false},{"nct_id":"NCT05335707","title":"Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}